Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Parkin Antikörper (AA 361-465)

PARK2 Reaktivität: Ratte WB, ELISA, IF (cc), IF (p), IHC (p), FACS, IHC (fro) Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN735578
  • Target Alle Parkin (PARK2) Antikörper anzeigen
    Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
    Bindungsspezifität
    • 17
    • 17
    • 15
    • 9
    • 9
    • 7
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 361-465
    Reaktivität
    • 78
    • 27
    • 27
    • 6
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    Ratte
    Wirt
    • 103
    • 7
    • 1
    Kaninchen
    Klonalität
    • 104
    • 7
    Polyklonal
    Konjugat
    • 56
    • 6
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 1
    Dieser Parkin Antikörper ist unkonjugiert
    Applikation
    • 99
    • 39
    • 38
    • 38
    • 22
    • 20
    • 17
    • 17
    • 8
    • 5
    • 4
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Kreuzreaktivität
    Ratte
    Homologie
    Human,Mouse,Pig
    Aufreinigung
    Purified by Protein A.
    Immunogen
    KLH conjugated synthetic peptide derived from human E3 ubiquitin-protein ligase parkin
    Isotyp
    IgG
    Top Product
    Discover our top product PARK2 Primärantikörper
  • Applikationshinweise
    WB 1:300-5000
    ELISA 1:500-1000
    FCM 1:20-100
    IHC-P 1:200-400
    IHC-F 1:100-500
    IF(IHC-P) 1:50-200
    IF(IHC-F) 1:50-200
    IF(ICC) 1:50-200
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    1 μg/μL
    Buffer
    0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
    Haltbarkeit
    12 months
  • Li, Zhang, Wang, Liu, Yang, Liu, Lu: "Neuroprotective effects of extract of Acanthopanax senticosus harms on SH-SY5Y cells overexpressing wild-type or A53T mutant ?-synuclein." in: Phytomedicine : international journal of phytotherapy and phytopharmacology, Vol. 21, Issue 5, pp. 704-11, (2014) (PubMed).

  • Target
    Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
    Andere Bezeichnung
    PARK2 (PARK2 Produkte)
    Synonyme
    CG10523 antikoerper, Dmel\\CG10523 antikoerper, Dpark antikoerper, SD01679 antikoerper, dpk antikoerper, AR-JP antikoerper, LPRS2 antikoerper, PDJ antikoerper, PRKN antikoerper, Park antikoerper, Prkn antikoerper, si:ch211-123f21.1 antikoerper, zgc:112390 antikoerper, pdr-1 antikoerper, PARK2 antikoerper, parkin antikoerper, parkin RBR E3 ubiquitin protein ligase antikoerper, Parkinson disease (autosomal recessive, juvenile) 2, parkin antikoerper, park antikoerper, PRKN antikoerper, Prkn antikoerper, prkn antikoerper, CpipJ_CPIJ014867 antikoerper, Park2 antikoerper
    Hintergrund

    Synonyms: PDJ, PRKN, AR-JP, LPRS2, E3 ubiquitin-protein ligase parkin, Parkinson juvenile disease protein 2, Parkinson disease protein 2, PARK2

    Background: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, TOMM2, USP3, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria (mitophagy) by the ubiquitination of mitochondrial proteins such as TOMM2, RHOT1/MIRO1 and USP3 (PubMed:24896179). Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome, possibly playing a role in the regulation of neuron death. Limits the production of reactive oxygen species (ROS). Regulates cyclin-E during neuronal apoptosis. In collaboration with CHPF isoform 2, may enhance cell viability and protect cells from oxidative stress. Independently of its ubiquitin ligase activity, protects from apoptosis by the transcriptional repression of p53/TP53. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. May represent a tumor suppressor gene.

    Gen-ID
    5071
    UniProt
    O60260
    Pathways
    Autophagie, Ubiquitin Proteasome Pathway
Sie sind hier:
Kundenservice